Summary:
In adults with type 2 diabetes mellitus, Empagliflozin treatment significantly altered the plasma lipidome, identifying distinct lipid signatures compared to baseline lipid profiles observed at one and twelve weeks, though it was associated with potential subgroup-specific lipid profile changes.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus. |
| Intervention | Empagliflozin treatment, administered over a period of 12 weeks. |
| Comparison | Baseline plasma lipidome profiles prior to Empagliflozin treatment. |
| Outcome | Empagliflozin-modulated plasma lipid profiles revealed distinct lipid signature changes at both week 1 and week 12. Five lipid changes were consistent across time points, and three of these showed directionally consistent alterations. Lipid profile changes were associated with clinical traits and subgroup-specific variations. |
Source: Bauer, Katrin I., et al. “Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial.” Read article here.
